These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 30391462)

  • 1. Elevated expression of Twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma.
    Kaishang Z; Xue P; Shaozhong Z; Yingying F; Yan Z; Chanjun S; Zhenzhen L; Xiangnan L
    Life Sci; 2018 Dec; 215():159-169. PubMed ID: 30391462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma.
    Su X; Wan Y; Xie L; Lin X; Zhao H; Ju X; Fang A
    Med Sci Monit; 2019 Sep; 25():6691-6701. PubMed ID: 31489957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
    Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
    Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.
    Li L; Liu YD; Zhan YT; Zhu YH; Li Y; Xie D; Guan XY
    Thorac Cancer; 2018 Jul; 9(7):775-784. PubMed ID: 29722145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma.
    Yu C; Hou L; Cui H; Zhang L; Tan X; Leng X; Li Y
    Future Oncol; 2018 Oct; 14(24):2483-2492. PubMed ID: 29756998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
    Chen D; Luo L; Liang C
    PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of TWF1 promotes lung adenocarcinoma progression and is associated with poor prognosis in cancer patients through the MMP1 signaling pathway.
    Zhai K; Jiang N; Wen JF; Zhang X; Liu T; Long KJ; Ke XX; Xu G; Chen C
    J Thorac Dis; 2023 May; 15(5):2644-2658. PubMed ID: 37324107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival.
    Chen J; Chen H; Yang H; Dai H
    Biomed Pharmacother; 2018 Apr; 100():233-239. PubMed ID: 29432994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
    Liu X; Chen L; Zhang T
    Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
    PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
    Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
    Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA VPS9D1-AS1 overexpression predicts a poor prognosis in non-small cell lung cancer.
    Tan J; Yang L
    Biomed Pharmacother; 2018 Oct; 106():1600-1606. PubMed ID: 30119235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis.
    Gao Z; Shi R; Yuan K; Wang Y
    Tumour Biol; 2016 Nov; 37(11):14979-14987. PubMed ID: 27655285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.